Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

3DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Pxs-5505, 2409963-83-1, Do94e28wyw, 2-buten-1-amine, 3-fluoro-4-(8-quinolinylsulfonyl)-, (2z)-, Unii-do94e28wyw, Schembl21693445

Molecular Formula

C₁₃H₁₃FN₂O₂S

Molecular Weight

280.32 g/mol

InChI Key

DHXXLGDTPFPYRH-WDZFZDKYSA-N

FDA UNII

DO94E28WYW

Pan-LOX Inhibitor PXS-5505 is an orally available, small-molecule, irreversible inhibitor of all lysyl oxidases (LOX) family members, with potential antifibrotic activity. Upon oral administration, pan-LOX inhibitor PXS-5505 targets, binds to and inhibits the activity of all enzymes in the LOX family. This prevents the post-translational oxidative deamination of lysine residues on target proteins, including collagen and elastin, and reduces the formation of deaminated lysine (allysine), the formation of inter- and intramolecular cross-linkages and may prevent remodeling of the extracellular matrix (ECM), thereby reducing fibrotic tissue formation in certain chronic fibrotic diseases. LOX is often upregulated in fibrotic tissue and plays a key role in fibrosis.

1 2D Structure

PXS-5505

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(Z)-3-fluoro-4-quinolin-8-ylsulfonylbut-2-en-1-amine

2.1.2 InChI

InChI=1S/C13H13FN2O2S/c14-11(6-7-15)9-19(17,18)12-5-1-3-10-4-2-8-16-13(10)12/h1-6,8H,7,9,15H2/b11-6-

2.1.3 InChI Key

DHXXLGDTPFPYRH-WDZFZDKYSA-N

2.1.4 Canonical SMILES

C1=CC2=C(C(=C1)S(=O)(=O)CC(=CCN)F)N=CC=C2

2.1.5 Isomeric SMILES

C1=CC2=C(C(=C1)S(=O)(=O)C/C(=C/CN)/F)N=CC=C2

2.2 Other Identifiers

2.2.1 UNII

DO94E28WYW

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Pxs-5505

2. 2409963-83-1

3. Do94e28wyw

4. 2-buten-1-amine, 3-fluoro-4-(8-quinolinylsulfonyl)-, (2z)-

5. Unii-do94e28wyw

6. Schembl21693445

7. Glxc-25899

8. Dwn63831

9. Ex-a4912

10. Hy-138625

11. Cs-0159641

12. (z)-3-fluoro-4-quinolin-8-ylsulfonylbut-2-en-1-amine

13. (z)-3-fluoro-4-(quinolin-8-ylsulfonyl)but-2-en-1-amine

2.4 Create Date

2020-06-27

3 Chemical and Physical Properties

Molecular Formula	C₁₃H₁₃FN₂O₂S
Molecular Weight	280.32 g/mol
XLogP3	0.4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	4
Exact Mass	280.06817700 g/mol
Monoisotopic Mass	280.06817700 g/mol
Topological Polar Surface Area	81.4 Å²
Heavy Atom Count	19
Formal Charge	0
Complexity	430
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	1
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1